Neuphoria Therapeutics Inc.
Price Action
Technical Summary
CONSOLIDATINGNeuphoria Therapeutics Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 17), showing significant lag compared to the market leaders. Earnings contraction of 101% provides fundamental context to the price action. However, RSI is deeply oversold at 25, suggesting potential for a mean-reversion bounce.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.29 | -19.81% | BELOW |
| 50 SMA | $4.79 | -28.25% | BELOW |
| 100 SMA | $4.63 | -25.63% | BELOW |
| 150 SMA | $4.44 | -22.45% | BELOW |
| 200 SMA | $5.67 | -39.29% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NEUP in an uptrend right now?
NEUP has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is NEUP overbought or oversold?
NEUP's RSI (14) is 25. The stock is oversold (RSI < 30), which could indicate a bounce opportunity.
Is NEUP outperforming the market?
NEUP has a Relative Strength (RS) Rating of 17 out of 99. NEUP is currently lagging the broader market.
Where is NEUP in its 52-week range?
NEUP is trading at $3.44, which is 16% of its 52-week high ($21.40) and 1% above its 52-week low ($3.19).
How volatile is NEUP?
NEUP has a Beta of 1.38 and 52-week volatility of 125%. It's more volatile than the S&P 500 - expect bigger swings.